Dual-Action Toothpaste For Halitosis: A Randomized Controlled Trial

This study aimed to evaluate the efficacy of a novel dual-action toothpaste containing domiphen bromide, IPMP, sodium copper chlorophyllin, and actinidin in reducing oral volatile sulfur compounds (VSCs) associated with halitosis. A 6-week randomized, double-blind, placebo-controlled trial was conducted with 100 halitosis patients, equally randomized to either the test group (dual-action toothpaste) or control group (placebo toothpaste). VSC levels (H₂S, CH₃SH, CH₃SSCH₃) were measured at baseline, 1, 2, and 6 weeks using OralChroma™. A mixed-effects model analyzed longitudinal data, with Cohen’s d calculating effect sizes. The test group demonstrated a significant 42.8% reduction in total VSCs by week 6 (p < 0.001), outperforming the control group (+17.9%). Individual VSC components showed marked decreases: H₂S (42.3%), CH₃SH (38.7%), and CH₃SSCH₃ (51.2%) (all p < 0.01). The effect size increased over time (d = 1.18 at 6 weeks), with noticeable improvement as early as week 1 (d = 0.68). The dual-action toothpaste, combining antibacterial (domiphen/IPMP) and enzymatic degradation (chlorophyllin/actinidin) mechanisms, provides rapid (1-week onset) and sustained (6-week efficacy) halitosis relief, offering a clinically validated treatment alternative.